Jérôme Desrame

Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)

Jérémie H. Lefèvre, Laurent Mineur, Salma Kotti et al. · Journal of Clinical Oncology · 2016 · 462 citations

Rectal Tumor, Surgical Oncology, Health Sciences +15

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

Thierry André, David Tougeron, Guillaume Piessen et al. · Journal of Clinical Oncology · 2022 · 345 citations · Full text

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Thierry André, Déwi Vernerey, Laurent Mineur et al. · Journal of Clinical Oncology · 2018 · 169 citations

Dfs Events, Surgical Oncology, Oncology +14

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study

Franck Pagès, Thierry André, Déwi Vernerey et al. · Annals of Oncology · 2020 · 151 citations · Full text

Medicine, Cancer Management, Immunology +7

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study

Stéfano Kim, Éric François, Thierry André et al. · The Lancet Oncology · 2018 · 140 citations

Gastrointestinal Oncology, Medicine, Metronomic Therapy +6